BillionToOne (BLLN) Q3 2025 earnings summary

Executive summary

• Achieved Q3 2025 revenue of $83.5 million, up 117% year-over-year, with strong growth in both prenatal and oncology testing and 165,000 tests delivered, a 51% increase YoY.

• Transitioned to profitability with Q3 2025 GAAP operating income of $9.6 million (11.5% margin) and net income of $1.5 million, reversing prior year losses.

• Raised $314 million in gross proceeds ($286.4 million net) from a November IPO, significantly strengthening the balance sheet.

• Focused on differentiated molecular diagnostics in prenatal and oncology, leveraging proprietary technology and exclusive companion diagnostic partnerships.

• Published multiple peer-reviewed studies validating product superiority and expanded payor contracts to cover approximately 235 million lives.

Financial highlights

• Q3 2025 revenue reached $83.5 million, up from $38.4 million in Q3 2024, with prenatal revenue at $74.8 million (up 101–102% YoY) and oncology revenue at $8.7 million (up 664–7.6x YoY).

• Gross margin expanded to 70% in Q3 2025 from 53% a year earlier, driven by higher ASPs and lower cost per test ($151, down 10% YoY).

• Operating margin was 11.5% in Q3 2025, with net income per diluted share of $0.10.

• Cash and equivalents at quarter-end were $195.2 million, with additional IPO proceeds post-Q3.

• Adjusted EBITDA for Q3 2025 was $14.2 million, up from $(8.8) million in Q3 2024.

Outlook and guidance

• 2025 full-year revenue guidance set at $293–$299 million, representing 92–96% growth over 2024.

• Q4 2025 revenue expected between $84–$90 million, up 86–100% year-over-year.

• Positive GAAP operating income projected for both Q4 and full year 2025.

• Management expects continued revenue growth driven by increased test volumes and higher ASPs, with further details for 2026 to be provided at the JPMorgan Healthcare Conference.

• Sufficient liquidity to fund operations for at least the next 12 months following the IPO.